BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21050067)

  • 1. A high-throughput screening strategy to overcome virus instability.
    Rasmussen L; Maddox C; Moore BP; Severson W; White EL
    Assay Drug Dev Technol; 2011 Apr; 9(2):184-90. PubMed ID: 21050067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phenotypic High-Throughput Screen with RSV-Infected Primary Human Small Airway Epithelial Cells (SAECs).
    Gobel J; Gartland M; Gurley SH; Kadwell S; Gillie D; Moore C; Goetz A
    J Biomol Screen; 2015 Jul; 20(6):729-38. PubMed ID: 25862685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel diversity-oriented synthesis-derived respiratory syncytial virus inhibitors identified via a high throughput replicon-based screen.
    Duvall JR; VerPlank L; Ludeke B; McLeod SM; Lee MD; Vishwanathan K; Mulrooney CA; Le Quement S; Yu Q; Palmer MA; Fleming P; Fearns R; Foley MA; Scherer CA
    Antiviral Res; 2016 Jul; 131():19-25. PubMed ID: 27059228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus.
    Chung DH; Moore BP; Matharu DS; Golden JE; Maddox C; Rasmussen L; Sosa MI; Ananthan S; White EL; Jia F; Jonsson CB; Severson WE
    Virol J; 2013 Jan; 10():19. PubMed ID: 23302182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput screening of active compounds against human respiratory syncytial virus.
    Fu YH; Xu ZX; Jiang N; Zheng YP; Rameix-Welti MA; Jiao YY; Peng XL; Wang Y; Eleouet JF; Cen S; He JS
    Virology; 2019 Sep; 535():171-178. PubMed ID: 31306912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclopiazonic acid, an inhibitor of calcium-dependent ATPases with antiviral activity against human respiratory syncytial virus.
    Cui R; Wang Y; Wang L; Li G; Lan K; Altmeyer R; Zou G
    Antiviral Res; 2016 Aug; 132():38-45. PubMed ID: 27210812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Druggable Pocket at the Nucleocapsid/Phosphoprotein Interaction Site of Human Respiratory Syncytial Virus.
    Ouizougun-Oubari M; Pereira N; Tarus B; Galloux M; Lassoued S; Fix J; Tortorici MA; Hoos S; Baron B; England P; Desmaële D; Couvreur P; Bontems F; Rey FA; Eléouët JF; Sizun C; Slama-Schwok A; Duquerroy S
    J Virol; 2015 Nov; 89(21):11129-43. PubMed ID: 26246564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral effect of cimicifugin from Cimicifuga foetida against human respiratory syncytial virus.
    Wang KC; Chang JS; Lin LT; Chiang LC; Lin CC
    Am J Chin Med; 2012; 40(5):1033-45. PubMed ID: 22928833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex.
    Cox RM; Toots M; Yoon JJ; Sourimant J; Ludeke B; Fearns R; Bourque E; Patti J; Lee E; Vernachio J; Plemper RK
    J Biol Chem; 2018 Oct; 293(43):16761-16777. PubMed ID: 30206124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory syncytial virus: prospects for new and emerging therapeutics.
    Jorquera PA; Tripp RA
    Expert Rev Respir Med; 2017 Aug; 11(8):609-615. PubMed ID: 28574729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.
    Blockus S; Sake SM; Wetzke M; Grethe C; Graalmann T; Pils M; Le Goffic R; Galloux M; Prochnow H; Rox K; Hüttel S; Rupcic Z; Wiegmann B; Dijkman R; Rameix-Welti MA; Eléouët JF; Duprex WP; Thiel V; Hansen G; Brönstrup M; Haid S; Pietschmann T
    Antiviral Res; 2020 May; 177():104774. PubMed ID: 32197980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advances in Developing Antiviral Therapies for Respiratory Syncytial Virus.
    Shook BC; Lin K
    Top Curr Chem (Cham); 2017 Apr; 375(2):40. PubMed ID: 28324595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.
    Perron M; Stray K; Kinkade A; Theodore D; Lee G; Eisenberg E; Sangi M; Gilbert BE; Jordan R; Piedra PA; Toms GL; Mackman R; Cihlar T
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1264-73. PubMed ID: 26666922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay.
    Do LAH; Tse R; Nathanielsz J; Anderson J; Ong DS; Chappell K; Mulholland K; Licciardi PV
    J Vis Exp; 2019 Jan; (143):. PubMed ID: 30741261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of novel respiratory syncytial virus inhibitors identified by high throughput screen.
    Laganas VA; Dunn EF; McLaughlin RE; Tiong-Yip CL; Yuzhakov O; Isabella VM; Hill P; Yu Q
    Antiviral Res; 2015 Mar; 115():71-4. PubMed ID: 25542974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors.
    Feng S; Li C; Chen D; Zheng X; Yun H; Gao L; Shen HC
    Eur J Med Chem; 2017 Sep; 138():1147-1157. PubMed ID: 28772235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two novel fusion inhibitors of human respiratory syncytial virus.
    Lundin A; Bergström T; Bendrioua L; Kann N; Adamiak B; Trybala E
    Antiviral Res; 2010 Dec; 88(3):317-24. PubMed ID: 20965215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Small Molecule Combinations against Respiratory Syncytial Virus In Vitro.
    Gao Y; Cao J; Xing P; Altmeyer R; Zhang Y
    Molecules; 2021 Apr; 26(9):. PubMed ID: 33946996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The alpha-1 subunit of the Na+,K+-ATPase (ATP1A1) is required for macropinocytic entry of respiratory syncytial virus (RSV) in human respiratory epithelial cells.
    Lingemann M; McCarty T; Liu X; Buchholz UJ; Surman S; Martin SE; Collins PL; Munir S
    PLoS Pathog; 2019 Aug; 15(8):e1007963. PubMed ID: 31381610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor.
    Coates M; Brookes D; Kim YI; Allen H; Fordyce EAF; Meals EA; Colley T; Ciana CL; Parra GF; Sherbukhin V; Stockwell JA; Thomas JC; Hunt SF; Anderson-Dring L; Onions ST; Cass L; Murray PJ; Ito K; Strong P; DeVincenzo JP; Rapeport G
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.